| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
The capacity of orvepitant (Compound 3a) to functionally inhibit substance P (SP)-induced cytosolic Ca2+ release in human neurokinin-1 receptor (hNK1)-CHO cells was another way that the compound was identified. When orvitamin (0.3–10 nM) was added to the agonist SP after it had been preincubated for an hour at 37°C, the agonist concentration–response curve became insurmountably antagonistic. The apparent pKB value of Orvepitant is 10.30[1].
|
|---|---|
| ln Vivo |
The number of postures seen at 1 mg/kg (34.9% reduction), 3 mg/kg (36.6% reduction), and 10 mg/kg (46.4% reduction) demonstrated a dose-dependent way upon treatment with Ovitan (Compound 3a; 0.3-10 mg/kg; oral; marmoset), suggesting that the compound may have anxiolytic-like effects [1]. In rats, Ovitan (Compound 3a) has an oral bioavailability (F) of 17% and a plasma clearance (Clp) of 29 mL/min/kg in rats and 55% in dogs. 6 mL/min/kg is the medium. A dog can live for 6.1 hours, but a rat can live for 2.3 hours. Five minutes following an intravenous administration of a dose of 1 mg/kg of Orvepitant, a B/P value of 1.2 was noted in relation to rat brain penetration [1].
|
| Animal Protocol |
Animal/Disease Models: Marmoset Human Threat Test (HTT) [1]
Doses: 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg Route of Administration: Oral Experimental Results: Dose-dependent reduction in quantity at 1 Posture was observed at mg/kg (34.9% reduction), 3 mg/kg (36.6% reduction), and 10 mg/kg (46.4% reduction). |
| References |
|
| Molecular Formula |
C35H39F7N4O6
|
|---|---|
| Molecular Weight |
744.71
|
| Exact Mass |
744.276
|
| CAS # |
579475-24-4
|
| PubChem CID |
44225656
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
6.322
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
52
|
| Complexity |
1140
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=C(C=CC(=C1)F)[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN5[C@H](C4)CCC5=O.C(=C\C(=O)O)\C(=O)O
|
| InChi Key |
IPACOHTZCSBGBV-WUXDIRCFSA-N
|
| InChi Code |
InChI=1S/C31H35F7N4O2.C4H4O4/c1-18-12-23(32)4-6-26(18)27-16-24(40-10-11-41-25(17-40)5-7-28(41)43)8-9-42(27)29(44)39(3)19(2)20-13-21(30(33,34)35)15-22(14-20)31(36,37)38;5-3(6)1-2-4(7)8/h4,6,12-15,19,24-25,27H,5,7-11,16-17H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t19-,24+,25+,27-;/m1./s1
|
| Chemical Name |
(2R,4S)-4-[(8aS)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide;(Z)-but-2-enedioic acid
|
| Synonyms |
GW 823296B; GW823296B; GW-823296B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~30 mg/mL (~40.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (6.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (6.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (6.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3428 mL | 6.7140 mL | 13.4280 mL | |
| 5 mM | 0.2686 mL | 1.3428 mL | 2.6856 mL | |
| 10 mM | 0.1343 mL | 0.6714 mL | 1.3428 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
